CinCor Pharma
Cincinnati, US · Founded 2018 · Delaware corporation · 2 known investors
Advancing clinical candidates for cardiovascular, metabolic and kidney diseases. (NASDAQ: CINC) (Acquired by AstraZeneca)
Founders & leadership
MD
Marc de GaridelExecutive
Investors · 2
Reported raises · per SEC filings
Form D private placements$142.9M disclosed across 1 round · 2021
▶$142.9MraisedOct 2021 · 22 investors · BiotechnologyRule 506(b)
▶$142.9MraisedOct 2021 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marc de GaridelExecutive Officer, Director
- Offering amount
- $142.9M
- Amount sold
- $142.9M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does CinCor Pharma do?
- Advancing clinical candidates for cardiovascular, metabolic and kidney diseases. (NASDAQ: CINC) (Acquired by AstraZeneca)
- Who are CinCor Pharma's investors?
- CinCor Pharma's investors include Sofinnova Partners, Sofinnova Ventures.
- How much funding has CinCor Pharma raised?
- CinCor Pharma has disclosed $142.9M raised across 1 round.
- Where is CinCor Pharma headquartered?
- CinCor Pharma is headquartered in Cincinnati, US.